$NTLA

Intellia Therapeutics (NTLA) appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings extensive experience in rare disease therapies and will lead clinical development and regulatory affairs. The company is advancing its CRISPR gene editing pipeline, including Phase 3 trials for transthyretin amyloidosis.

B. Riley upgraded Skyworks (SWKS) to Buy with a $107 price target, citing faster Qorvo deal closure. Evercore ISI upgraded Procter & Gamble (PG) to Outperform with a $166 target. Deutsche Bank upgraded Penn Entertainment (PENN) to Buy with a $25 target. StoneX upgraded Texas Roadhouse (TXRH) to Buy with a $200 target. Citi upgraded JetBlue (JBLU) to Neutral with a $4.50 target. Berenberg downgraded Nike (NKE) to Sell with a $27.50 target, citing its smaller sportswear position.

Barclays initiated coverage of Intellia Therapeutics with an Underweight rating and a $8 price target. The company's stock has risen 41.82% year-to-date, trading at $12.75. The rating is based on valuation, EPS revisions, and visibility metrics.

ARK Innovation ETF, managed by Cathie Wood, bought $81M in Nvidia, $13.1M in Broadcom, and $7.3M in CoreWeave, while selling $111.1M in AMD. Other purchases included Intellia Therapeutics, BWX Technologies, and Tesla. Sales included 10x Genomics, Tempus AI, Alphabet, and Palantir.

ARK ETFs bought shares of Rocket Lab (RKLB), BWX Technologies (BWXT), Intellia Therapeutics (NTLA), and Veracyte (VCYT), while selling shares of Alphabet (GOOGL), Palantir (PLTR), and Zillow (Z). The transactions reflect ARK's strategy of investing in high-growth sectors and trimming positions in established tech companies.

U.S. stock futures were mixed early Thursday, with AI and semiconductor shares in focus after Micron Technology reported strong earnings. Nasdaq futures rose 0.6%, S&P 500 futures were flat, while Dow and Russell 2000 futures dipped 0.4%. Several companies, including Oracle, Alphabet, Meta, and Synopsys, saw premarket gains due to AI-related developments. Nike and Tesla are among the trending stocks ahead of their earnings and delivery updates.

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

Intellia Therapeutics (NTLA) awaits FDA decision on lonvo-z for hereditary angioedema (HAE) on March 10, with Phase III data showing 87% attack-rate reduction. The company is preparing for commercial launch, though pricing is undecided. Intellia also advances its TTR amyloidosis study and reports $630M in cash, with a $300M debt facility for funding into 2028.

Intellia Therapeutics (NTLA) outlined a two-track strategy at the Morgan Stanley conference. The FDA accepted its biologics license application for lonvo-z, with a PDUFA date of March 10, 2025. The company reported strong HAE data, including an 87% reduction in attack rate. Intellia has $630M in cash and expects to fund operations into 2028. It is preparing a targeted launch for lonvo-z and is advancing its TTR amyloidosis program, which faces design and competitive questions.

Intellia Therapeutics (NTLA) secured a $400M credit facility with OrbiMed, drawing $75M initially. The remaining $325M is contingent on milestones. The facility has a 9.15% minimum interest rate. NTLA has $628.4M in cash but reported a $106.6M Q2 net loss. The financing supports potential U.S. launch of lonvo-z and other programs.